Biotechnology
DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative
NEW YORK, May 6, 2021 /PRNewswire/ -- DarwinHealth, a New York City-based biotechnology company, today announced a scientific research collaboration with Bristol-Myers Squibb Company (NYSE: BMY). The research collaboration, theNovel Cancer Target Initiative (NCTI), employs quantitative systems b...
2021-05-06 20:31
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
SHANGHAI and HONG KONG, May 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolog...
2021-05-06 11:28
664
CSafe Global Providing Thermal Protection for COVID-19 Vaccine Shipments from BioNTech Facility
The tailor-made double-wall VIP insulated shipper provides 10+ days of temperature protection for vaccine shipments from BioNTech's facility with minimal dry ice. DAYTON, Ohio, May 5, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in active, passive parcel and cell and gene temperature...
2021-05-05 20:00
769
Cellares Raises $82M To Solve The Biggest Hurdles In Cell Therapy Manufacturing
Decheng Capital and Eclipse Ventures lead Series B round, bringing total funding to over$100 million SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Cellares Corporation , a life sciences technology company that automates cell therapy manufacturing, today announced it has secured$82 mil...
2021-05-05 18:00
870
Warning about potential impacts on humanity through embryo gene editing
SINGAPORE, May 5, 2021 /PRNewswire/ -- A global conference on human fertility has been warned of huge societal and ethical challenges regulating advances in gene editing in assisted reproduction. Speaking at the 10th Congress of the Asian Pacific Initiative of Reproduction (ASPIRE), DrCatherin...
2021-05-05 16:38
743
CNN's Saved by the Future meets the innovators transforming the healthcare industry
HONG KONG, May 5, 2021 /PRNewswire/ -- In the latest episode of CNN's 'Saved by
the Future', hostNicki Shields
2021-05-05 10:47
817
Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)
HANGZHOU and SHAOXING, China, May 5, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) today announces the positive Phase IIa clinical results of ASC22 (Envafolimab), which is a first-in-class, subcutaneously administered PD-L1 antibody for chronic hepatitis B (CHB) functional cure. ASC2...
2021-05-05 08:30
948
IVM-MS2, 'The Most Compact All-in-One IntraVital Two-Photon Microscopy System in the World'
IVIM Technology, Inc. has released the most compact all-in-one intravital two-photon microscope, "IVM-MS2." IVIM Technology, Inc. is the world's first start-up that commercializes all-in-one integrated intravital microscopy equipment. Our equipment uses innovative intravital microscopy (IVM) tech...
2021-05-03 23:47
1074
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory di...
2021-05-03 20:30
2776
BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction
VANCOUVER, BC, May 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreement ("Agreement") with BioElpida S.A.S. ("BioElpida") of Lyon,Franc...
2021-05-03 20:00
1497
Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study
82 Patient Pivotal cohort expected to commence in second half of 2021 BEDMINSTER, N.J. and SINGAPORE, April 30, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors...
2021-04-30 18:00
1134
BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(R) Diagnostic
Commercial trademark application FILED for CoviDTH® diagnostic cancer vaccine platform patent coverageexpanded to NOW include over 12 tumor types VANCOUVER, B.C., April 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "the Company"), the world ...
2021-04-29 20:56
1641
Artificial Intelligence helps IVF patients avoid invasive embryo genetic testing
SAN FRANCISCO, April 29, 2021 /PRNewswire/ -- Life Whisperer, the fertility arm of AI healthcare company Presagen, has made a significant breakthrough in using artificial intelligence to non-invasively help embryologists rank and select genetically healthy embryos in IVF. Currently, PGT-A geneti...
2021-04-29 19:47
840
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
SHANGHAI and HONG KONG, April 29, 2021 /PRNewswire/ -- With the official release and implementation ofthe Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of n...
2021-04-29 08:34
1310
Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration
SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2021-04-29 08:00
2637
Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2
- Topline results expected in 2nd half 2021; 475 out of a 834 target patients randomized in ESSENCE-2 - Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed - Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and External Disease HEIDELBERG, Germany and C...
2021-04-28 20:00
716
CROs dMed and Clinipace Merge to Accelerate Customer Success
SHANGHAI and MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- dMed Global, a full-service Clinical Contract Research Organization (CRO) based inShanghai, China, and Clinipace Incorporated, a full-service Clinical CRO with headquarters inNorth Carolina, USA, announced today that the two companies...
2021-04-28 20:00
1161
Turn Biotechnologies completes latest round of funding
Silicon Valley investor Khosla Ventures joins esteemed group of global investors backing Turn MOUNTAIN VIEW, Calif., April 28, 2021 /PRNewswire/ -- Turn Biotechnologies, a company developing novel RNA medicines for untreatable age-related conditions, today announced that it has closed its latest...
2021-04-28 19:50
1228
DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone
SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has c...
2021-04-27 09:23
1412
EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
PROVIDENCE, R.I., April 27, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication"Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" inFrontiers in Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administrati...
2021-04-27 09:00
1345
Week's Top Stories
Most Reposted
Digitalization to Advance Thailand's Hospital System
[Picked up by 100 media titles]
2021-05-04 11:00
P&G Encourages Women To Talk About Imposter Syndrome in #RealDeal campaign with Lazada
[Picked up by 95 media titles]
2021-05-03 09:00
Digitizing The Nation, Telkom Indonesia Posted 11.5% Growth in Net Income During Pandemic
[Picked up by 95 media titles]
2021-05-03 13:50Tsangs Group Signs Collaboration Agreement with HBK Department of Projects
[Picked up by 92 media titles]
2021-05-04 15:00UOB and American Express(R) launch cashback card that meets the needs of consumers who want unlimited cashback on all card spend
[Picked up by 91 media titles]
2021-05-04 15:13
Most Read
Shanghai Electric Releases 2020 Corporate Social Responsibility Report
2021-04-30 23:25
9951
FME Launches 3D Crane Anti-Collision System with Ouster Lidar
2021-04-29 10:44
8323
AAC's WLG Hybrid Camera Lens Global debut marks a new dawn in Mobile Photography
2021-04-30 22:29
6867
MGM China Reports 2021 First Quarter Financial Data
2021-04-29 06:22
5766
Jianpu Technology Inc. Files 2019 Annual Report on Form 20-F
2021-05-01 04:50
5374